Bioventus Inc. (NASDAQ:BVS) currently has a daily average trading volume of 1.72M but it saw 858254 shares traded on Thursday. With a market cap of 154.17M USD, stock’s current market price of $2.63 came rising about 2.73 while comparing to the previous closing price of $2.56. In past 52 weeks, the stock remained buoying in the range of price level as high as $10.02 and as low as $0.80. In the recent trading on the day, stock has struck highest price mark of $2.82 while lowest mark touched by it was $2.4713.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Taking a look at 20-day trading activity of Bioventus Inc. (BVS) gives us an average price of $1.40, while its current price level is -73.75% below from 52-week high level whereas it is 228.79% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.26 while that of 200 days or SMA-200 reads an average of $3.65. A closer look into the stock’s movement over the week reveals that its volatility is standing at 30.71% during that period while stretching the period over a month that decreases to 15.61%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 87.88 which implies that the stock is in overbought territory.
Data by FactSet Research shows that 3 analysts have issued their ratings for the stock. 1 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 0 analysts suggested the investors to Buy the stock while 2 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Underweight for the stock and that issued by Wall Street to investors is Hold.
Over the week, BVS’s stock price is moving 80.14% up while it is 136.94% when we observe its performance for the past one month. Year-to-date it is 0.77% up and over the past year, the stock is showing a downside performance of -68.95%.
The latest quarterly earnings report issued by the company was for quarter ended 3/30/2023, when its quarterly earnings per share (EPS) of -$0.26 beaten by the consensus estimate of -$0.15 for the same. For BVS, analysts are forecasting an EPS-growth rate of -300.00% for current year and estimate for EPS growth in next year is 152.90%. In next quarter, company is expected to be making quarterly sales of $119.94 million as analysts are expecting the sales for current fiscal year at $493.14 million and seeing the company making $514.43 million in sales next year. Moreover, analysts are in estimates of $129.23 million for current-quarter revenue.
Currently, Bioventus Inc.’s total number of outstanding shares is 61.93M with 15.63% of that held by the insiders while 64.72% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -27.30% and return on equity (ROE) at -32.60%. It has a 11.79 of forward P/E ratio. Stock has a price to book (P/B) ratio of 0.51 while price to sale or P/S ratio amounts to 0.30. Its return on asset (ROA) is -9.80% on average.
As per SEC documents, Vanguard Total Stock Market ETF shunned 673,435 of company’s common stock of worth $0.68 million as per recent closing price of the stock. Vanguard Total Stock Market ETF is not the only institutional holder which restructured its stake in Bioventus Inc., as iShares Russell 2000 ETF dumped 632,271 shares of worth $0.64 million to bring its holdings to a total of 9280.0 shares.
Leave a Reply